Posted by Michael Wonder on 26 Oct 2021
Geron enters new innovative licensing and access pathway in the United Kingdom for imetelstat
25 October 2021 - Innovation Passport Designation Awarded to Imetelstat for the Treatment of Lower Risk Myelodysplastic Syndromes.
Geron Corporation today announced that imetelstat, the Company’s first in class telomerase inhibitor, has been granted an Innovation Passport, which is the first prescribed entry point to the Innovative Licensing and Access Pathway launched in the United Kingdom by the Medicines and Healthcare products Regulatory Agency in January 2021, post-Brexit.
